Subscribe to our Newsletters !!
Whether in a peaceful corner of a suburban backyar
Biopharma plants run on tight schedules, so every
Dr. Mohammed Enayat’s recent testimony on his ag
The life science group Sartorius has successfully
Unlike other medications, Vyvanse (Lisdexamfetamin
Since it’s an ingredient in so many foods, you h
In our cover story, we shine a spotlight on “ The Magazine
Mumbai, India; April 30, 2019: – Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce receipt of final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan Tablets 5mg & 10mg from the United States Food and Drug Administration (US FDA).
rnrn rn
Cipla’s Ambrisentan Tablets 5mg & 10mg is AB-rated generic therapeutic equivalent version of Gilead Sciences, Inc’s Letairis®. Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening.
The U.S. Sales of Letairis® Tablets USP stood at $943 million in 2018. The product is available for shipping immediately.
